Aktuellt
SENASTE
Redeye still regards Optomed’s current share price levels as an attractive long-term entry point, following its case review (prompted by a change in analysts). We apply a new Base Case of EUR 9 (13). Optomed offers a treatment-altering solution for a large unmet medical need and is closing in on a US rollout that should boost sales considerably over the coming two to three years.
LÄS MER
